J. Craig Venter, the biologist renowned for leading the private effort to sequence the first human genome and founding groundbreaking ventures including Celera Genomics and Human Longevity Inc., has launched his latest enterprise: Diploid Genomics. The new company, revealed on January 23, 2026, aims to harness artificial intelligence to unlock the full potential of human genomic data, moving beyond static reference genomes to dynamic, continuously updated models that reflect real-world genetic diversity and environmental interactions.

Diploid Genomics will build what Venter describes as “the most complete and diverse human genome knowledge base ever assembled.” The platform will aggregate whole-genome sequencing data from millions of individuals across global populations, with a deliberate emphasis on underrepresented ancestries to address longstanding biases in genomic research. Advanced multimodal AI models combining genomic sequences with transcriptomics, proteomics, epigenomics, and real-world clinical outcomes will enable the discovery of previously hidden causal variants, gene-environment interactions, and polygenic risk patterns that drive common and rare diseases.

The company’s approach differs from earlier genomics initiatives by treating the human genome as a living, evolving dataset. Rather than producing a single reference assembly, Diploid will maintain a continuously updated, population-scale “pan-genome” that evolves with new sequencing data, clinical annotations, and environmental exposures. Machine learning algorithms will simulate variant effects, predict functional consequences, and prioritise therapeutic targets with far greater precision than traditional association studies.

Venter, who serves as Chairman and Chief Scientific Officer, emphasised the urgency of this next phase in genomics: “We sequenced the first human genome 25 years ago. Now, with AI and massive diverse datasets, we can finally move from reading the code to truly understanding and rewriting it for human health. Diploid Genomics is built to make that leap.”

The startup has already secured substantial early funding from a mix of venture capital firms, strategic investors, and philanthropic sources focused on global health equity. Initial applications will target complex diseases with strong genetic components such as cardiometabolic disorders, neurodegenerative conditions, autoimmune diseases, and certain cancers while supporting drug discovery partners in identifying genetically validated targets with higher success probabilities.

Diploid Genomics plans to offer commercial services starting in late 2026, including high-resolution personal genome interpretation for consumers, pharmaceutical target discovery platforms, and research tools for academic and biotech partners. The company has committed to ethical data governance, robust privacy protections, and equitable representation in its datasets to ensure benefits reach diverse global populations.

This launch reinforces Venter’s lifelong mission to democratise genomic knowledge and accelerate the translation of genetic insights into clinical impact. With AI now enabling analysis at scales previously unimaginable, Diploid Genomics could play a pivotal role in ushering in an era of truly predictive and preventive human genomics.